SO
MLYS icon

STRS Ohio’s Mineralys Therapeutics MLYS Stock Holding History

STRS Ohio’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,400
Closed -$208K – 2252
2025
Q2 		$208K Sell
15,400
-7,200
-32% -$104K ﹤0.01% 1651
2025
Q1 		$359K Sell
22,600
-4,300
-16% -$49.5K ﹤0.01% 1334
2024
Q4 		$331K Hold
26,900
– – ﹤0.01% 1349
2024
Q3 		$326K Buy
26,900
+23,100
+608% +$280K ﹤0.01% 1420
2024
Q2 		$44.5K Buy
3,800
+2,200
+138% +$27.7K ﹤0.01% 1811
2024
Q1 		$20K Sell
1,600
-900
-36% -$11.1K ﹤0.01% 1852
2023
Q4 		$21K Hold
2,500
– – ﹤0.01% 1846
2023
Q3 		$23K Hold
2,500
– – ﹤0.01% 1866
2023
Q2 		$42K Hold
2,500
– – ﹤0.01% 1826
2023
Q1 		$39K Buy
+2,500
New +$42.1K ﹤0.01% 1811

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

STRS Ohio's MLYS Position: Q3 2025 in Review

STRS Ohio sold out of Mineralys Therapeutics (MLYS) in Q3 2025, closing a stake of 15,400 shares — an estimated $208K sold.

STRS Ohio first reported a position in MLYS in Q1 2023 and held it in 10 quarters. The position peaked at $359K in Q1 2025. 193 funds tracked by Wall St. Rank hold MLYS as of Q3 2025.

  • STRS Ohio reported no remaining Mineralys Therapeutics position as of Q3 2025 after selling out during the quarter.
  • STRS Ohio sold 15,400 Mineralys Therapeutics shares in Q3 2025, an estimated $208K.
  • STRS Ohio first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 10 quarters.
  • STRS Ohio's Mineralys Therapeutics position peaked at $359K in Q1 2025.
  • 193 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2025.

Based on STRS Ohio's 13F filing for Q3 2025, filed 30 Oct 2025.